AI-discovered lung drug reverses aging markers in study
An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of aging, pointing to broader potential use of the treatment, according to its developer.
An AI-discovered drug called rentosertib, developed by Insilico Medicine, has shown promise in reversing biological signs of aging, as revealed by a midstage study. According to the results published in Nature Biotechnology, the drug helped reduce biological age in patients by six different aging clocks that measure chemical changes in the body.
Those who received a placebo saw no change in their biological age on the same clocks. CEO of the Hong Kong-listed company, Alex Zhavoronkov, stated that a lower biological age is associated with a later death. However, he cautioned that the results are still preliminary and the long-term health effects of the drug in larger populations are unknown. The study included 42 patients with a chronic lung disease.
Written by urgent.news from Japan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
